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annual rate of 3% in the base case analysis. We conducted 
sensitivity analyses to investigate how variation in overall 
survival with and without RT, RT demand, projected GDP 
growth rates, and operational and infrastructure costs per 
fraction impacted projections. 
Results:  In the base case “rapid” investment scenario, a 
total of 24,383,261 discounted life years are gained by 2035 
through scaling up radiotherapy capacity. This represents 
4,131,981 LYs in upper-middle, 11,006,360 LYs in lower-
middle, and 9,245,240 LYs in low-income countries. This 
results in a total of 124,389,936,346 USD discounted net 
monetary benefits accrued through productivity gains. 
Different investment scenarios and costing packages impact 
the rate of return.  
Conclusion: The health and economic benefits from 
improving access to radiotherapy capacity are projected to 
be substantial. Despite the capital costs associated with 
implementing radiotherapy infrastructure, the adoption of a 
long-term perspective demonstrates that in addition to the 
large health gains generated, the economic gains of 
radiotherapy investment are likely to offset programmatic 
costs. Scaling up radiotherapy capacity may be considered a 
cost-saving intervention, which may warrant priority within 
the health budgets of LMIC.  
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The structure and mechanics of tumour vasculature as well as 
oxygen consumption by the cancer determines the levels of 
tumour hypoxia.  Vascular structure is affected by 
remodeling that can be altered after agents inhibition of 
oncogenic signaling in the cancer cells. Inhibition of the RAS-
PI3K signalling  pathway leads to morphological changes 
resulting in increased perfusion and decreased vascular 
tortuosity. At the same time inhibition of the pathway also 
leads to decreased oxygen consumption. Together then the 
result of RAS-PI3K inhibition is decreased tumour hypoxia and 
increased tumour growth delay after radiation therapy.   
While decreased hypoxia during radiation therapy should 
increase efficacy, recurrence of tumours after therapy could 
be expected to require neoangiogenesis. Inhibition of 
angiogenesis using an antibody to notch ligand DLL4 led to 
superadditive reduction in tumour regrowth after radiation.  
However these studies cannot fully describe the events that 
might occur after fractionated radiation.  After fractionated 
radiation we find increased deposition of the potent 
angiogenic stimulator, FGF2 by recruited myeloid cells.  In 
another oncologic setting, liver metastasis, we can show that 
myeloid cells recruited to the liver colonies are induced to 
express FGF2 and that inhibition of FGF2 reduced the liver 
colony growth. These studies raise the possibility of FGF2 as 
a target for therapy in the setting of fractionated radiation 
therapy.  
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Purpose: Inhibition of the PI3K/mTOR pathway decreases 
hypoxia within SQ20B human head and neck cancer 
xenografts. We set out to understand the molecular 
mechanism underlying this observation. 
Experimental Design:  We measured oxygen consumption 
using both a Clark electrode and an extracellular flux 
analyzer. We made these measurements after various 
pharmacologic and genetic manipulations.   
Results: Pharmacologic inhibition of the PI3K/mTOR pathway 
or genetic inhibition of Akt/PI3K decreased the oxygen 
consumption rate (OCR) in vitro in SQ20B and other cell lines 
by 30-40%.  Pharmacologic inhibition of this pathway 
increased phosphorylation of the E1a subunit of the pyruvate 
dehydrogenase (PDH) complex on Ser293, which inhibits 
activity of this critical gatekeeper of mitochondrial 
respiration. Expressing wild type PTEN in a doxycycline-
inducible manner in a cell line with mutant PTEN led to an 
increase in PDH-E1a phosphorylation and a decrease in OCR. 
Pre-treatment of SQ20B cells with dichloroacetate (DCA), 
which inhibits PDH-E1a phosphorylation by inhibiting 
dehydrogenase kinases (PDKs), reversed the decrease in OCR 
in response to PI3K/Akt/mTOR inhibition. Likewise, 
introduction of exogenous PDH-E1a that contains serine to 
alanine mutations, which can no longer be regulated by 
phosphorylation, also blunted the decrease in OCR seen with 
PI3K/mTOR inhibition.  
Conclusions: Our findings highlight an association between 
the PI3K/mTOR pathway and tumor cell oxygen consumption 
that is regulated in part by PDH phosphorylation.  These 
results have important implications for understanding the 
effects PI3K pathway activation in tumor metabolism and also 
in designing cancer therapy trials that use inhibitors of this 
pathway.   
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Purpose/Objective: The anti-diabetic biguanides metformin 
(MET) and phenformin (PHEN) works by partial inhibition of 
respiration, and may have antineoplastic effects. Inhibition 
of respiration induces energetic stress and activation of the 
AMPK stress-signaling pathway possibly causing reduced 
tumor growth or cell death. Inhibition of respiration may also 
improve tumor oxygenation and thus radiosensitize tumors. 
Unfortunately, nearly all studies demonstrating anticancer 
effects of biguanides have used supraphysiological drug 
concentrations in vitro and ignored that cellular uptake 
depends on organic cation transporters (OCTs). The purpose 
of this study is to provide evidence for or against directly 
